Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Nelson

Showing results (441-450 of 442) with videos related to

Pageof 45
Sort By:
You have reached the last page of results.This site can display upto 442 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trialsMark Nelson, Keikawus Arastéh, Bonaventura Clotet, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeksBenoit Trottier, Sharon Walmsley, Jacques Reynes, et al.
Pageof 45

Showing results (441-450 of 442) with videos related to

Sort By:
Pageof 45
You have reached the last page of results.This site can display upto 442 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trialsMark Nelson, Keikawus Arastéh, Bonaventura Clotet, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2005
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeksBenoit Trottier, Sharon Walmsley, Jacques Reynes, et al.
Pageof 45